Refine
Year of publication
Language
- English (54)
Has Fulltext
- yes (54)
Is part of the Bibliography
- no (54)
Keywords
- BRD4 (3)
- PROTAC (3)
- Structural biology (3)
- Biochemistry (2)
- Biophysical chemistry (2)
- DYRK1A (2)
- E2F-1 (2)
- PAD4 (2)
- X-ray structure analysis (2)
- bromodomains (2)
- cancer (2)
- citrullination (2)
- epigenetic (2)
- epigenetics (2)
- immune response (2)
- inflammation (2)
- molecular docking (2)
- phenotypic screening (2)
- protein kinase inhibitor (2)
- AML (1)
- ATAD2 (1)
- ATP binding (1)
- Apoptosis (1)
- Aurora kinase (1)
- BET inhibitor (1)
- BET inhibitors (1)
- BET proteins (1)
- BH3 mimetics (1)
- BRD2 (1)
- BROMO-10 (1)
- Binding analysis (1)
- BioID (1)
- Bromodomänen (1)
- CNS melanoma (1)
- COVID-19 (1)
- CPTAC (1)
- CRBN (1)
- CRC65 (1)
- CRISPR/Cas9 (1)
- Cancer (1)
- Cas9 inhibitor (1)
- Cell biology (1)
- Cell membranes (1)
- Cell signalling (1)
- Chaperones (1)
- Chemical biology (1)
- Chemical tools (1)
- Chemische Sonden (1)
- Chlorides (1)
- Crystal structure (1)
- DNA damage (1)
- Degrader design (1)
- Differential Scanning Calorimetry (DSF) (1)
- Drug discovery (1)
- Drug screening (1)
- E. coli (1)
- E3 Ligase (1)
- ERK3 (1)
- Enzymes (1)
- Epigenetik (1)
- GABARAP (1)
- Guanine nucleotide exchange factors (1)
- Guanosine triphosphatase (1)
- HDAC inhibitor (1)
- High performance liquid chromatography (1)
- Hydrogen bonding (1)
- IAP (1)
- Indoles (1)
- Isothermal Titration Calorimetry (1)
- Isothermal Titration Calorimetry (ITC) (1)
- KCGS (1)
- Kd determination (1)
- Kinase inhibitors (1)
- Kinases (1)
- LC3 (1)
- LIMK1 (1)
- LIMK2 (1)
- LIR motifs (1)
- Library screening (1)
- Luciferase (1)
- MAPK6 (1)
- Mechanisms of disease (1)
- Medicinal chemistry (1)
- Medizinische Chemie (1)
- Molecular glue (1)
- NMR spectroscopy (1)
- NanoBRET (1)
- New E3-ligase ligands (1)
- PIM kinases (1)
- Phosphorylation (1)
- Rhabdomyosarcoma (1)
- SARS-CoV-2 (1)
- STK3 (1)
- Salt inducible kinase 2 (SIK2) (1)
- Small molecules (1)
- Strukturbasiertes Design (1)
- UCN-01 (1)
- ULK4 (1)
- Ubiquitin (1)
- Unc-51-like kinase (1)
- VHL (1)
- Vesicles (1)
- X-ray crystallography (1)
- accessory proteins (1)
- actin cytoskeleton dynamics (1)
- adenosine–arginine conjugate (1)
- alkaloid (1)
- androgen receptor (1)
- anilinopyrimidine (1)
- atypical MAPK kinase (1)
- autophagy (1)
- benzazepinone (1)
- biophysics (1)
- bisubstrate inhibitors (1)
- bromodomain (1)
- bromodomain inhibitor (1)
- castration-resistant prostate cancer (1)
- catalytic mechanism (1)
- cell biology (1)
- cell cycle (1)
- cell-free protein synthesis (1)
- cellular uptake and localization (1)
- chemical probes (1)
- chemical-induced proximity (1)
- chemogenomic set (1)
- chemogenomics (1)
- chromatin (1)
- chromosomal instability (1)
- co-crystal structure (1)
- co-crystallization (1)
- cofilin (1)
- combined therapy (1)
- covalent inhibitors (1)
- cytotoxicity (1)
- docking studies (1)
- drug discovery (1)
- drug response (1)
- druggable genome (1)
- dual BET/HDAC inhibitor (1)
- enhancer of transcription (1)
- epithelial cells (1)
- epithelium (1)
- evolution (1)
- fluorescent probes (1)
- forkhead box protein o1 (1)
- gastric cancer (1)
- genes (1)
- genome editing (1)
- harmine (1)
- high content imaging (1)
- indole (1)
- interaction partners (1)
- intrinsically disordered region (1)
- kinase (1)
- kinase inhibitor (1)
- kinase inhibitors (1)
- kinetically trapped state (1)
- machine learning (1)
- medicinal chemistry (1)
- mitosis (1)
- monoamine oxidase A (1)
- mouse (1)
- nephelometry (1)
- nonstructural proteins (1)
- oocytes (1)
- ovarian cancer (1)
- p63 (1)
- paclitaxel sensitization (1)
- pancreatic ductal adenocarcinoma (1)
- patient stratification (1)
- personalized medicine (1)
- phenotype (1)
- phosphorylation (1)
- protein X-ray crystallography (1)
- protein kinase (1)
- proteomics (1)
- proto-oncogene proteins c-akt (1)
- pseudokinase (1)
- quality control (1)
- resveratrol (1)
- rna (1)
- signal transduction (1)
- small molecules (1)
- small-molecule inhibitor (1)
- solubility (1)
- spindle mispositioning (1)
- spring-loaded activation (1)
- structural biolog (1)
- structural proteins (1)
- structure-based design (1)
- structure–activity relationships (1)
- sulfamide (1)
- the small molecule inhibitor MRIA9 (1)
- tp63 gene (1)
- transcription factor (1)
- understudied kinase (1)
- π-clamp (1)
Institute
- Biochemie, Chemie und Pharmazie (25)
- Buchmann Institut für Molekulare Lebenswissenschaften (BMLS) (16)
- Pharmazie (15)
- Medizin (9)
- Biochemie und Chemie (8)
- Biowissenschaften (6)
- Exzellenzcluster Makromolekulare Komplexe (4)
- Georg-Speyer-Haus (2)
- MPI für Biophysik (2)
- Zentrum für Biomolekulare Magnetische Resonanz (BMRZ) (2)
The nsP3 macrodomain is a conserved protein interaction module that plays essential regulatory roles in host immune response by recognizing and removing posttranslational ADP-ribosylation sites during SARS-CoV-2 infection. Thus, targeting this protein domain may offer a therapeutic strategy to combat the current and future virus pandemics. To assist inhibitor development efforts, we report here a comprehensive set of macrodomain crystal structures complexed with diverse naturally-occurring nucleotides, small molecules as well as nucleotide analogues including GS-441524 and its phosphorylated analogue, active metabolites of remdesivir. The presented data strengthen our understanding of the SARS-CoV-2 macrodomain structural plasticity and it provides chemical starting points for future inhibitor development.
The highly infectious disease COVID-19 caused by the Betacoronavirus SARS-CoV-2 poses a severe threat to humanity and demands the redirection of scientific efforts and criteria to organized research projects. The international COVID19-NMR consortium seeks to provide such new approaches by gathering scientific expertise worldwide. In particular, making available viral proteins and RNAs will pave the way to understanding the SARS-CoV-2 molecular components in detail. The research in COVID19-NMR and the resources provided through the consortium are fully disclosed to accelerate access and exploitation. NMR investigations of the viral molecular components are designated to provide the essential basis for further work, including macromolecular interaction studies and high-throughput drug screening. Here, we present the extensive catalog of a holistic SARS-CoV-2 protein preparation approach based on the consortium’s collective efforts. We provide protocols for the large-scale production of more than 80% of all SARS-CoV-2 proteins or essential parts of them. Several of the proteins were produced in more than one laboratory, demonstrating the high interoperability between NMR groups worldwide. For the majority of proteins, we can produce isotope-labeled samples of HSQC-grade. Together with several NMR chemical shift assignments made publicly available on covid19-nmr.com, we here provide highly valuable resources for the production of SARS-CoV-2 proteins in isotope-labeled form.
The Kinase Chemogenomic Set (KCGS): an open science resource for kinase vulnerability identification
(2021)
We describe the assembly and annotation of a chemogenomic set of protein kinase inhibitors as an open science resource for studying kinase biology. The set only includes inhibitors that show potent kinase inhibition and a narrow spectrum of activity when screened across a large panel of kinase biochemical assays. Currently, the set contains 187 inhibitors that cover 215 human kinases. The kinase chemogenomic set (KCGS), current Version 1.0, is the most highly annotated set of selective kinase inhibitors available to researchers for use in cell-based screens.
Dimerization of Taspase1 activates an intrinsic serine protease function that leads to the catalytic Thr234 residue, which allows to catalyze the consensus sequence Q−3X−2D−1⋅G1X2D3D4, present in Trithorax family members and TFIIA. Noteworthy, Taspase1 performs only a single hydrolytic step on substrate proteins, which makes it impossible to screen for inhibitors in a classical screening approach. Here, we report the development of an HTRF reporter assay that allowed the identification of an inhibitor, Closantel sodium, that inhibits Taspase1 in a noncovalent fashion (IC50 = 1.6 μM). The novel inhibitor interferes with the dimerization step and/or the intrinsic serine protease function of the proenzyme. Of interest, Taspase1 is required to activate the oncogenic functions of the leukemogenic AF4-MLL fusion protein and was shown in several studies to be overexpressed in many solid tumors. Therefore, the inhibitor may be useful for further validation of Taspase1 as a target for cancer therapy.
The function of the p53 transcription factor family is dependent on several folded domains. In addition to a DNA-binding domain, members of this family contain an oligomerization domain. p63 and p73 also contain a C-terminal Sterile α-motif domain. Inhibition of most transcription factors is difficult as most of them lack deep pockets that can be targeted by small organic molecules. Genetic knock-out procedures are powerful in identifying the overall function of a protein, but they do not easily allow one to investigate roles of individual domains. Here we describe the characterization of Designed Ankyrin Repeat Proteins (DARPins) that were selected as tight binders against all folded domains of p63. We determine binding affinities as well as specificities within the p53 protein family and show that DARPins can be used as intracellular inhibitors for the modulation of transcriptional activity. By selectively inhibiting DNA binding of the ΔNp63α isoform that competes with p53 for the same promoter sites, we show that p53 can be reactivated. We further show that inhibiting the DNA binding activity stabilizes p63, thus providing evidence for a transcriptionally regulated negative feedback loop. Furthermore, the ability of DARPins to bind to the DNA-binding domain and the Sterile α-motif domain within the dimeric-only and DNA-binding incompetent conformation of TAp63α suggests a high structural plasticity within this special conformation. In addition, the developed DARPins can also be used to specifically detect p63 in cell culture and in primary tissue and thus constitute a very versatile research tool for studying the function of p63.
BH3 mimetics are promising novel anticancer therapeutics. By selectively inhibiting BCL-2, BCL-xL, or MCL-1 (i.e. ABT-199, A-1331852, S63845) they shift the balance of pro- and anti-apoptotic proteins in favor of apoptosis. As Bromodomain and Extra Terminal (BET) protein inhibitors promote pro-apoptotic rebalancing, we evaluated the potential of the BET inhibitor JQ1 in combination with ABT-199, A-1331852 or S63845 in rhabdomyosarcoma (RMS) cells. The strongest synergistic interaction was identified for JQ1/A-1331852 and JQ1/S63845 co-treatment, which reduced cell viability and long-term clonogenic survival. Mechanistic studies revealed that JQ1 upregulated BIM and NOXA accompanied by downregulation of BCL-xL, promoting pro-apoptotic rebalancing of BCL-2 proteins. JQ1/A-1331852 and JQ1/S63845 co-treatment enhanced this pro-apoptotic rebalancing and triggered BAK- and BAX-dependent apoptosis since a) genetic silencing of BIM, BAK or BAX, b) inhibition of caspase activity with zVAD.fmk and c) overexpression of BCL-2 all rescued JQ1/A-1331852- and JQ1/S63845-induced cell death. Interestingly, NOXA played a different role in both treatments, as genetic silencing of NOXA significantly rescued from JQ1/A-1331852-mediated apoptosis but not from JQ1/S63845-mediated apoptosis. In summary, JQ1/A-1331852 and JQ1/S63845 co-treatment represent new promising therapeutic strategies to synergistically trigger mitochondrial apoptosis in RMS.
Malfunction of the actin cytoskeleton is linked to numerous human diseases including neurological disorders and cancer. LIMK1 (LIM domain kinase 1) and its paralogue LIMK2 are two closely related kinases that control actin cytoskeleton dynamics. Consequently, they are potential therapeutic targets for the treatment of such diseases. In the present review, we describe the LIMK conformational space and its dependence on ligand binding. Furthermore, we explain the unique catalytic mechanism of the kinase, shedding light on substrate recognition and how LIMK activity is regulated. The structural features are evaluated for implications on the drug discovery process. Finally, potential future directions for targeting LIMKs pharmacologically, also beyond just inhibiting the kinase domain, are discussed.
A toolbox for the generation of chemical probes for Baculovirus IAP Repeat containing proteins
(2022)
E3 ligases constitute a large and diverse family of proteins that play a central role in regulating protein homeostasis by recruiting substrate proteins via recruitment domains to the proteasomal degradation machinery. Small molecules can either inhibit, modulate or hijack E3 function. The latter class of small molecules led to the development of selective protein degraders, such as PROTACs (PROteolysis TArgeting Chimeras), that recruit protein targets to the ubiquitin system leading to a new class of pharmacologically active drugs and to new therapeutic options. Recent efforts have focused on the E3 family of Baculovirus IAP Repeat (BIR) domains that comprise a structurally conserved but diverse 70 amino acid long protein interaction domain. In the human proteome, 16 BIR domains have been identified, among them promising drug targets such as the Inhibitors of Apoptosis (IAP) family, that typically contain three BIR domains (BIR1, BIR2, and BIR3). To date, this target area lacks assay tools that would allow comprehensive evaluation of inhibitor selectivity. As a consequence, the selectivity of current BIR domain targeting inhibitors is unknown. To this end, we developed assays that allow determination of inhibitor selectivity in vitro as well as in cellulo. Using this toolbox, we have characterized available BIR domain inhibitors. The characterized chemical starting points and selectivity data will be the basis for the generation of new chemical probes for IAP proteins with well-characterized mode of action and provide the basis for future drug discovery efforts and the development of PROTACs and molecular glues.
Phenotypical screening is a widely used approach in drug discovery for the identification of small molecules with cellular activities. However, functional annotation of identified hits often poses a challenge. The development of small molecules with narrow or exclusive target selectivity such as chemical probes and chemogenomic (CG) libraries, greatly diminishes this challenge, but non-specific effects caused by compound toxicity or interference with basic cellular functions still pose a problem to associate phenotypic readouts with molecular targets. Hence, each compound should ideally be comprehensively characterized regarding its effects on general cell functions. Here, we report an optimized live-cell multiplexed assay that classifies cells based on nuclear morphology, presenting an excellent indicator for cellular responses such as early apoptosis and necrosis. This basic readout in combination with the detection of other general cell damaging activities of small molecules such as changes in cytoskeletal morphology, cell cycle and mitochondrial health provides a comprehensive time-dependent characterization of the effect of small molecules on cellular health in a single experiment. The developed high-content assay offers multi-dimensional comprehensive characterization that can be used to delineate generic effects regarding cell functions and cell viability, allowing an assessment of compound suitability for subsequent detailed phenotypic and mechanistic studies.
The multistep PROTAC (PROteolysis TArgeting Chimeras) degradation process poses challenges for their rational development, as rate limiting steps determining PROTAC efficiency remain largely unknown. Moreover, the slow throughput of currently used endpoint assays does not allow the comprehensive analysis of larger series of PROTACs. Here we developed cell-based assays using NanoLuciferase and HaloTags, that allow measuring PROTAC induced degradation and ternary complex formation kinetics and stability in cells. Using PROTACs developed for degradation of WDR5, the characterization of the mode of action of these PROTACs in the early degradation cascade revealed a key role of ternary complex formation and stability. Comparing a series of ternary complex crystal structures highlighted the importance of an efficient E3-target interface for ternary complex stability. The developed assays outline a strategy for the rational optimization of PROTACs using a series of live cell assays monitoring key steps of the early PROTAC induced degradation pathway.
Significance The multistep PROTAC induced degradation process of a POI poses a significant challenge for the rational design of these bifunctional small molecules as critical steps that limit PROTAC efficacy cannot be easily assayed at required throughput. In addition, the cellular location of the POI may pose additional challenges as some cellular compartments, such as the nucleus, may not be easily reached by PROTAC molecules and the targeted E3 ligases may not be present in this cellular compartment. We propose therefore a comprehensive assay panel for PROTACs evaluation in cellular environments using a sensor system that allows continuous monitoring of the protein levels of the endogenous POI. We developed a cell line expressing WDR5 from its endogenous locus in fusion with a small sequence tag (HiBIT) that can be reconstituted to functional NanoLuciferase (NLuc). This system allowed continuous monitoring of endogenous WDR5 levels in cells and together with HaloTag system also the continuous monitoring of ternary complex (E3, WDR5 and PROTAC) formation. As this assay can be run at high throughput, we used this versatile system monitoring three diverse chemical series of WDR5 PROTACs that markedly differ in their degradation properties. Monitoring cell penetration, binary complex formation (PROTAC-WDR5 and PROTAC-VHL) as well as ternary complex formation we found that PROTAC efficiency highly correlated with synergy of ternary complex formation in cells. This study represents a first data set on diverse PROTACs studying this property in cellulo and it outlines a strategy for the rational optimization of PROTACs. It also provided kinetic data on ternary complex assembly and dissociation that may serve as a benchmark for future studies utilizing also kinetic properties for PROTAC development. Comparative structural studies revealed larger PROTAC mediated interaction surfaces for PROTACs that efficiently formed ternary complexes highlighting the utility of structure based optimization of PROTAC induced ternary complexes in the development process.